Kratom Supplement Marketers Dispute FDA Warning, Ask For Review
This article was originally published in The Rose Sheet
In addition to a review of the advisory announced by FDA Commissioner Gottlieb, a trade group petitions the agency for a meeting to allow stakeholders "to correct misstatements and factual errors on the science regarding the safety and addiction potential of kratom."
You may also be interested in...
FDA and FTC send joint warning letters to 11 US firms about 12 products marketed as unapproved drugs with claims about aiding in the treatment of opioid addiction and withdrawal. FDA also thanks CSPI for suggesting the agencies investigate a scourge of fraudulent drug-abuse withdrawal claims.
FDA and the Federal Trade Commission should bring immediate enforcement action against marketers of non-kratom dietary supplements promoted as opioid-withdrawal aids, says the Center for Science in the Public Interest in letters to the agency and commission Dec. 8. The nonprofit identified eight supplement products making opioid-withdrawal claims without sufficient science to support the statements.
American Kratom Association representatives also this week are lobbying state and local officials in Georgia to withdraw their findings linking 17 deaths directly to the use of kratom, and testifying at a Utah state legislative panel hearing on alternative pain remedies.